Viruses, Vol. 16, Pages 503: Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines

Viruses, Vol. 16, Pages 503: Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines Viruses doi: 10.3390/v16040503 Authors: Yıldız Răileanu Beissert Replicating RNA, including self-amplifying RNA (saRNA) and trans-amplifying RNA (taRNA), holds great potential for advancing the next generation of RNA-based vaccines. Unlike in vitro transcribed mRNA found in most current RNA vaccines, saRNA or taRNA can be massively replicated within cells in the presence of RNA-amplifying enzymes known as replicases. We recently demonstrated that this property could enhance immune responses with minimal injected RNA amounts. In saRNA-based vaccines, replicase and antigens are encoded on the same mRNA molecule, resulting in very long RNA sequences, which poses significant challenges in production, delivery, and stability. In taRNA-based vaccines, these challenges can be overcome by splitting the replication system into two parts: one that encodes replicase and the other that encodes a short antigen-encoding RNA called transreplicon. Here, we review the identification and use of transreplicon RNA in alphavirus research, with a focus on the development of novel taRNA technology as a state-of-the art vaccine platform. Additionally, we discuss remaining challenges essential to the clinical application and highlight the potential benefits related to the unique properties of this future vaccine platform.
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
More News: Vaccines | Virology